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Induction by Toxic-Shock-Syndrome Toxin-1 of a Circulating Tumor Necrosis 
Factor-Like Substance in Rabbits and of Immunoreactive Tumor Necrosis Factor 
and Interleukin-1 from Human Mononuclear Cells
Takashi Ikejima, Seijiro Okusawa, From the Department o f  Medicine, New England Medical
Jos W. M. van der Meer, and Charles A. Dinarello Center Hospitals and Tufts University School o f  Medicine,
Boston, Massachusetts
A shock-like syndrome was induced in rabbits by administering toxic-shock-syndrome 
toxin-1 (TSST-1); tumor necrosis factor (TNF)-like activity was detected in sera of rabbits
3.5 h after injection, as measured by cytotoxic effects on the tumorigenic L929 murine 
fibroblast cell line. Appearance of this activity in sera coincided with onset of significant 
shock-related hemodynamic changes. TSST-1 stimulated release of TNF-like material from 
rabbit mononuclear cells in culture. Human mononuclear cells also secreted a cytotoxic 
substance shown to be TNF by radioimmunoassay. Maximal TNF secretion was higher 
in human mononuclear cells stimulated with TSST-1 than in those stimulated with bac­
terial lipopolysaccharide. Lipopolysaccharide, however, was a more potent inducer of 
interleukin-1 a and interleukin-1 (3 from the same cells than was TSST-1. Because TNF and 
interleukin-1 act synergistically during induction of a shock-like state, these results sug­
gest that part of the TSST-l-induced shock is due to production of interleukin-1 and TNF.
Toxic shock syndrome is often a life-threatening dis­
ease for humans. The syndrome has been attributed 
to certain strains of Staphylococcus aureus [1, 2] that 
colonize the vagina or infect wounds. Despite a dra­
matic and sudden onset of fever, hypotension, and 
gastrointestinal disturbances, bacteremia has rarely 
been demonstrated. Therefore the constellation of 
signs and symptoms of the syndrome is likely to be 
due to toxemia.
The polypeptide exotoxin toxic-shock-syndrome 
toxin-1 (TSST-1) causes many of the acute manifesta­
tions of toxic shock syndrome, including fever, hy­
potension, and diarrhea, in animals. The precise 
mechanism of the toxin’s ability to induce the syn­
drome remains to be elucidated, but TSST-1 is clearly 
an inducer of the cytokine interleukin-1 (IL-1), and 
in turn IL-1 causes some, but not all, of the observed 
clinical and laboratory responses associated with 
toxic shock syndrome [3, 4].
However, another potent IL-1 inducer, endotoxin 
or lipopolysaccharide (LPS), also stimulates a differ­
ent cytokine, tumor necrosis factor (TNF) [5-8]. TNF
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is an endogenous pyrogen [9], and TNF shares with 
IL-1 many biologic functions. Recombinant IL-1 and 
TNF increase hepatic acute-phase protein synthesis
[10], decrease hepatic albumin synthesis [10, 11], in­
duce synovial collagenase and prostaglandin E2 [12], 
cause release of procoagulant activity from vascu­
lar endothelium [13], and inhibit lipoprotein lipase 
synthesis [14, 15]. We recently demonstrated that in­
jection of recombinant human IL-1 (3 or recombinant 
human TNF decreases systemic arterial pressure in 
the rabbit and that combined administration of IL-
1 and TNF is more potent than either cytokine alone 
in induction of a shock-like state [16].
Here we demonstrate that TSST-1 induces shock 
in the rabbit, as characterized by decreased mean ar­
terial pressure, systemic vascular resistance, and cen­
tral venous pressure (CVP). Death occurs subsequent 
to these hemodynamic changes. We detected a cir­
culating TNF-like activity during the TSST-l-induced 
shock in rabbits. We also quantified TNF-like activ­
ity in vitro after stimulation of rabbit mononuclear 
cells (MNCs) with TSST-1. Using both the bioassay 
and a specific RIA, we examined TSST-l-induced 
production of TNF in vitro from MNCs of human 
subjects. These data indicate cytokine-mediated 
hemodynamic changes in toxic shock syndrome.
Materials and Methods
Rabbit model fo r  hemodynamic changes. Fe­
male New Zealand white rabbits (weighing ^ 5  kg)
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were anesthetized with a single injection of 4 mg of 
xylazine/kg and 10 mg of ketamine/kg. This com­
bination of nonbarbituates has been used in previ­
ous studies in models of septic shock where experi­
mentally induced changes in hemodynamic parameters 
were shown to be unaffected by these anesthetics [16]. 
Catheters were placed in the left carotid artery (PE 
50), the pulmonary artery (no. 3 French Swan-Ganz), 
and the superior vena cava (PE 50) for continuous 
recording of arterial pressure and CVP and measure­
ment of cardiac output every 10 min.
After insertion of the catheters, hemodynamic 
changes were monitored for 60 min to determine 
baseline levels. During the experiments, blood sam­
ples removed from the carotid catheter were replaced 
by the same volume of saline. The total fluid (sa­
line) administered during the study was 6 mL/kg per
h. Cardiac output was measured by the thermodilu­
tion method. Systemic vascular resistance was cal­
culated as follows: (mean arterial pressure -  CVP) 
x  80/cardiac output (in dyne x  s/cm5).
TSST-1 was injected into the superior vena cava 
as a bolus over a 30-s period. Blood was withdrawn 
from the carotid artery catheter for white blood cell 
counts.
At 3-4 h after the injection of TSST-1 at 2 or 5
• 4
|ig/kg, the heart, submandibular gland, sublingual 
gland, esophagus, stomach, liver, pancreas, jejunum, 
ileum, colon, rectum, aorta, inferior vena cava, skin, 
ovary, thymus, and eyes were examined for gross 
changes. However, gross changes were observed only 
in the lungs.
Statistical analyses were done by applying one-way 
analysis of variance, where the post-TSST-1 values 
of an experimental group at a particular time were 
compared with the values of the same group immedi­
ately before injection. The values of various hemo­
dynamic parameters in five rabbits given saline dur­
ing the 3.5-h period were not different (P<  .05) from 
the values at zero-time.
TSST-1. TSST-1 was purchased from Toxin Tech­
nology (Madison, Wis). It was homogeneous on 
SDS-PAGE. TSST-1 at 100 ng/mL dissolved in endo­
toxin-free, ultrafiltered water contained <20 pg of 
endotoxin/mL, as measured by the Limulus amoe- 
bocyte lysate test (Associates of Cape Cod, Woods 
Hole, Mass). This Limulus lysate has a sensitivity 
of 20 pg of Escherichia coli LPS/mL (Sigma Chem­
ical Company, St. Louis).
Bioassay fo r  TNF-like activity. TNF-like activ­
ity was detected by TN F’s cytotoxic effect against
the tumorigenic murine fibroblast L929 (ATCC 
CCL1; American Type Culture Collection, Rockville, 
Md) [17]. L929 cells were cultured in flat-bottom, 
96-well microtiter plates (Becton Dickinson Co., Ox­
nard, Calif) at a density of 5.5 x  104 cells per well 
in RPMI 1640 culture medium (M. A. Bioproducts, 
Walkersville, Md) containing 5°7o fetal calf serum 
(Hyclone Laboratory, Logan, Utah), 2 mM  L-gluta- 
mine, 100 U of penicillin/mL, and 100 pig of strep- 
tomycin/mL. After incubation for 18 h, culture 
medium was removed, and recombinant human TNF 
(provided by Genentech, South San Francisco, Calif) 
as the standard or samples and actinomycin D (2 \ig 
per well; Sigma) were added. The cells were cultured 
for an additional 20 h. The culture medium was re­
moved, and the cells were stained with 0.1% crystal 
violet in 100% methanol for 20 min. OD600 was mea­
sured with an MR Microelisa Auto Reader® (Dy- 
natech, Alexandria, Va). Cytotoxicity was calculated 
as follows: percent cytotoxicity = (1 — [^ 4 of sampleZ4 
of control]) x  100.
Rabbit antisera to human TNF and human IL-1 
and specific RIAs. Immunization of rabbits with 
recombinant human TNF, recombinant human IL- 
la, and recombinant human IL-1 (3 was accomplished 
in complete Freund’s adjuvant. Monthly boosters 
were given in Freund’s incomplete adjuvant. Methods 
for RIA for human TNF were recently established 
by using this antiserum and 125I-labeled recombinant 
human TNF [18]. The RIAs for IL-la  and IL-13 do 
not detect IL-1 (3 or IL-la, respectively. Details con­
cerning the RIAs for IL -la  and IL-1 (3 have been 
reported recently [19,20]. Total (supernatant and cell- 
associated) TNF, IL-la, and IL-1 (3 from human 
MNCs were quantified by their respective and spe­
cific RIA.
Preparation o f  rabbit and human MNCs. Healthy 
human male volunteers or New Zealand white fe­
male rabbits were bled into heparinized (10 U/mL) 
syringes, and the MNC fraction was prepared by cen­
trifugation over Ficoll-Paque® (Pharmacia, Piscata- 
way, NJ; and Winthrop Laboratories, New York). 
MNCs were suspended at 5 x  106 cells/mL in 
endotoxin-free, ultrafiltered RPMI 1640 medium [21] 
containing heat-inactivated autologous human or 
rabbit serum (2%). One milliliter of the MNC sus­
pension was mixed with an equal volume of TSST-1 
or LPS at different dilutions in serum-free, 
ultrafiltered RPMI 1640 medium in 24-well culture 
plates and then incubated at 37 C in an atmosphere 
of 95% room air and 5% C 0 2 for 24 h. Culture su-
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Figure 1. TSST-l-induced hemody­
namic changes in rabbits after (A) a 
control bolus injection of 3 mL of
0.9% NaCl into five rabbits, (B) a bo­
lus injection (2 pig/kg) of TSST-1 into 
three rabbits, and (C) a bolus injection 
(5 ng/kg) of TSST-1 into three rabbits. 
Data are mean percent changes from 
the zero-time value for mean arterial 
pressure (•), cardiac output (O), and 
systemic vascular resistance (A) and 
mean change from the zero-time value 
for CVP (■).
pernatants or lysates were prepared. Lysates were ob­
tained by three freeze-and-thaw cycles.
Data analysis. Data obtained on production of 
the three cytokines by MNCs from several human 
volunteers were analyzed using the Scheffé F  test. 
This test compares variance between two groups; for 
example, the mean IL-1 P production induced by a 
given stimulant, such as TSST-1, in several volunteers 
compared with the production induced by LPS.
Results
TSST-1 induction o f  hypotension. Control rab­
bits injected with saline remained hemodynamically
stable for 180 min: Mean ± SD arterial pressure for 
five rabbits was 66 ±  3.0 mm Hg 30 min before in­
jection, 63.8 ± 3.3 mm Hg at 0 min (immediately 
after saline injection), 64.6 ± 3.6 mm Hg at 60 min, 
69 ± 4.2 mm Hg at 120 min, and 67 ± 4.6 mm Hg 
at 180 min (figure 1 A). Other hemodynamic param­
eters (cardiac output, systemic vascular resistance, 
and CVP) were not significantly changed (by analy­
sis of variance) throughout the experimental period. 
However, a bolus injection of TSST-1 at 2 pig/kg in­
duced considerable change in hemodynamic param­
eters (figure IB). Mean arterial pressure began to fall 
within 140 min and continuously declined to 42.3 
± 12.7 mm Hg at 210 min (28.4%). The decrease
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in mean arterial pressure was statistically significant 
at 190 min (P<  .05). However, the hypotension was 
not statistically significant before 190 min.
Injection of 5 \ig of TSST-l/kg induced a more 
pronounced hypotension in rabbits (figure 1C). The 
fall in mean arterial pressure began earlier (within 
80 min) in these rabbits than in rabbits treated with
2 |ig of TSST-l/kg. At 140 min, the mean arterial 
pressure reached 43.0 ± 10.7 mm Hg, and the de­
crease in mean arterial pressure in the TSST-1-treated 
group was significantly greater than the change in 
the control group injected with saline (P<  .05). From 
140 to 180 min, the mean arterial pressure remained 
between 43 and 45 mm Hg. However, the difference 
in mean arterial pressure between the TSST-1-treated 
group and the control group was more significant 
at 180 min (P <  .01) than at 140 min (P<  .05). After 
180 min, blood pressure progressively fell, and the 
rabbits died. Systemic vascular resistance also 
showed a dramatic decrease, in accordance with the 
marked fall in mean arterial pressure. By analysis 
of variance, compared with the value at 0 min (im­
mediately after the injection of TSST-1), the sig­
nificance of the fall in systemic vascular resistance 
was as follows: from 110 to 120 min, P < .05; from 
130 to 210 min, P < .01. CVP also fell, whereas 
cardiac output increased, and these changes showed 
similar levels of significance during these times.
During this time, white blood cell counts fell sig­
nificantly in the TSST-l-injected rabbits (figure 2), 
similar to the fall in mean arterial pressure, systemic 
vascular resistance, or CVP. White blood cell counts 
of rabbits receiving saline rose with time. These in­
creases may be caused by the preexperiment cathe­
ter placements or other stressful aspects of the pro­
cedure.
On gross observation, the lungs from control rab­
bits receiving saline appeared pink, with occasional 
areas of subpleural blood (1.5-2 mm in diameter). 
In contrast, the lungs of rabbits receiving TSST-1 at 
5.0 ng/kg showed diffuse surface hemorrhage and 
a liver-like appearance and consistency on inspec­
tion and palpation. In rabbits injected with 2 \ig of 
TSST-l/kg, the lungs appeared less affected in color, 
and marked hemorrhages were not observed.
Detection o f  TNF-like activity in serum o f  rab­
bits injected with TSST-1. Rabbit serum collected
3.5 h after injection of 2 jag of TSST-l/kg was cyto­
toxic for L929 cells (figure 3). The cytotoxicity we 
observed was not due to the high concentration of 
rabbit serum in the assay, because control preinjec-
Time (Hours)
Figure 2. Effect of TSST-1 on circulating white blood 
cells in rabbits for which data are shown in figure 1A (sa­
line control; □), IB (TSST-1 at 2 ng/kg; ♦), and 1C (TSST- 
1 at 5 ng/kg; D). Data are mean ± SE (bars) percent 
changes in numbers of white blood cells.
tion serum induced less cytotoxicity than the same 
concentration of the serum from TSST-l-injected 
rabbits. Pooled normal rabbit serum (10%) also did 
not change the sensitivity of L929 cells to various 
concentrations of recombinant human TNF (data 
not shown).
Detection o f  TNF-like activity in TSST-l-stimu- 
lated rabbit and human M N C  supernatants. TSST-1 
induced secretion of TNF-like activity from rabbit 
MNCs (table 1). Addition of 1% of these cell cul­
ture supernatants resulted in significant cytotoxic­
ity against L929 cells compared with unstimulated 
cell controls. Human MNCs stimulated with TSST- 
1 at 100 or 10 ng/mL released a cytotoxic substance 
or substances into the culture supernatant (figure 4). 
Addition of rabbit antiserum to human TNF 
markedly reduced the cytotoxicity of the MNC su­
pernatants, although 20% -30%  of the activity re­
mained unneutralized. Carryover of TSST-1 from the 
first MNC culture to the second culture (L929) had 
no effect on the cytotoxicity against L929 cells be­
cause culture medium containing TSST-1 without 
MNCs did not induce cytotoxicity. LPS at a concen­
tration of 100 or 10 ng/mL induced amounts of TNF- 
like activity similar to that induced by TSST-1.
Detection o f  human TNFy IL -la , and IL -ip  by 
RIA in TSST-l-stimulated MNCs. TSST-1 induced 
TNF production in MNC cultures from five human 
male donors in a dose-dependent manner as mea­
sured by RIA (figure 5). Variability in the amount
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Table 1. Percent cytotoxicity of supernatants from rab 
bit MNCs stimulated with TSST-1.
Dilution of MNC culture super­
natants in L929 cell culture (%)
rabbit MNCs 50 25 10 1
Control (no addition) 
TSST-1
0 0 2.2 0.1
1.25 |ig/mL 83.2 88.1 76.1 39.1
0.63 ng/mL 84.2 90.6 81.1 33.6
NOTE. Recombinant human TNF at concentrations of 2, 
1, and 0.25 ng/mL induced 77.2%, 41.4%, and 23.6% cytotox­
icity, respectively, for L929 cells.
Concentration of Rabbit Serum (%)
Figure 3. Cytotoxic activity in sera from rabbits obtained 
3.5 h after injection of 2 fig of TSST-l/kg (□; see figure 
IB). L929 cells were incubated overnight with dilutions 
of the serum in the presence of actinomycin D. As a posi­
tive control, recombinant human (rhu) TNF was used; cy­
totoxicity with this factor is shown {top). As a negative 
control, serum from the same rabbit, taken before injec­
tion of TSST-1, was tested (♦). Two different experiments 
are shown (middle and bottom).
of TNF (cell associated plus extracellular) produced 
by these donors was considerable. In donor 2, 2500 
pg of TNF/mL was induced by 10 ng of TSST-l/mL, 
whereas only 450 pg of TNF/mL was detected in do­
nor 3. We also measured TNF production from 
MNCs stimulated with LPS and compared this value 
with the stimulation by TSST-1. LPS (10 ng/mL) in­
duced 12.8 ng of TNF/mL in donor 1, whereas TSST- 
1 induced 1.25 ng/mL.
Because of the differences in the responses of hu­
man MNCs to different toxins, we undertook a 
detailed study examining the amount of immuno- 
reactive TNF, IL-1 a, and IL-1 [3 induced by various 
concentrations of TSST-1 or LPS in the same donor’s 
MNCs and as measured for each cytokine by RIA. 
Production of TNF (table 2) and IL-13 (table 3) was 
maximal when cells were stimulated by either 1 or 
10 ng of LPS/mL. IL-1 a  production (table 4), how-
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Figure 4. Bioassay for TNF in culture supernatant of 
human MNCs treated with TSST-1. Culture supernatant 
(20%) was assayed for cytotoxicity to L929 cells with (Ü) 
or without (■) 1% rabbit antiserum to human TNF. As­
says for TNF were also done in cultures without MNCs 
(22). Concentrations are in ng/mL. Concentrations of 
recombinant human TNF of 1 and 0.1 ng/mL induced 
100% and 42% cytotoxicity, respectively. The results were 
obtained from nine wells and had M0% variation. Results 
were similar in two other experiments. CTRL = control.
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Figure 5. Concentrations of total (supernatant plus cell- 
associated) TNF in human MNCs from donors 1-5 {from 
top to bottom) stimulated with TSST-1 or LPS. Samples 
were quantified by RIA for TNF. An asterisk indicates that 
the level of TNF was below the detection limit (80 pg/mL). 
N.D. = not done.
ever, continued to increase with increasing concen­
trations of LPS. For both IL-1 (3 and IL-1 a, LPS was 
a more potent inducer than TSST-1 was (100 ng/mL). 
Maximal IL-1 (3 production was 6.51 ± 3.17 ng/mL 
in the LPS-stimulated group, whereas the maximal 
production in the TSST-l-stimulated group was 2.91 
± 1.20 (P <  .05; table 3). IL-1 a  production was also 
higher in the LPS-stimulated group (22.41 ± 9.09 
ng/mL) than in the TSST-l-stimulated group (7.15 
± 4.35 ng/mL; P <  .05). On the other hand, TSST-1 
was a more potent inducer of TNF (9.83 ± 4.83 
ng/mL) than was LPS (4.31 ± 1.75 ng/mL; P <  .05). 
Figure 6 shows each individual’s maximal response 
to each toxin. TSST-1 clearly is, for most individu­
als studied, a more potent inducer of TNF than is 
LPS.
Discussion
The rabbit has been used widely as an animal model 
to elucidate the pathogenesis of toxic shock syn-
Table 2. RIA for TNF production in human MNCs 
stimulated with LPS or TSST-1.
LPS (ng/mL) TSST-1 (ng/mL)
Donor no.
mcuiuin
control 10 1.0 0.1 10 1.0 0.1
6 ND 7.6 7.8 1.6 5.2 4.9 1.8
7 ND 2.8 3.0 1.8 9.9 5.9 0.5
8 0.4 5.2 5.3 1.8 10.0 3.5 0.8
9 0.8 4.4 3.1 1.7 11.0 7.2 1.1
10 ND 3.7 3.1 1.5 20.0 1.7 0.6
11 0.6 4.5 5.0 2.6 10.8 4.0 1.0
12 0.6 2.8 3.0 1.7 4.4 3.7 0.6
13 ND 2.0 2.3 1.1 7.3 1.4 ND
NOTE. Total TNF (supernatant plus cell associated) was 
quantified. Samples were diluted 113, and concentrations were 
calculated from the sensitive portion of the standard curve. Fi­
nal concentrations (in ng/mL) of total TNF are shown. ND = 
not detectable.
drome [22]. Animal models for inducing the toxic- 
shock-like state usually use high doses of TSST-1, 
ranging from microgram to milligram quantities per 
kilogram of body weight [23], and under these con­
ditions, circulating IL-1 is clearly being produced [3]. 
Using anesthetized rabbits our previous studies dem­
onstrated that low doses of IL-1 induce reversible 
hypotension and, when given as a constant infusion, 
a shock-like state [16]. The time course of IL-l-in- 
duced hypotension was rapid, and the onset and 
recovery were nearly identical to those of pyrogenic 
responses [24].
Large doses (microgram to milligram quantities 
per kilogram of body weight) of LPS induce septic 
shock in animal models, and under these conditions 
both IL-1 and TNF are being produced. Human
Table 3. RIA for IL-ip production in human MNCs 
stimulated with LPS or TSST-1.
LPS (ng/mL) TSST-1 (ng/mL)
Donor no. control 10 1.0 0.1 10 1.0 0.1
6 ND 2.5 10.1 2.6 2.3 2.2 0.6
7 0.5 4.4 2.8 1.6 4.1 1.3 0.5
8 0.7 11.2 9.0 2.2 5.0 2.4 ND
9 ND 6.9 6.9 2.2 3.0 1.6 0.6
10 0.5 6.4 7.6 2.6 3.4 1.4 0.7
11 0.6 4.4 6.4 3.6 2.1 1.1 0.8
12 0.6 3.6 3.1 1.7 2.0 1.1 0.6
13 ND 1.9 1.9 1.1 1.4 0.6 0.5
NOTE. Total IL-113 (supernatant plus cell associated) was 
quantified. Samples were diluted 1:3, and concentrations were 
calculated from the sensitive portion of the standard curve. Fi­
nal concentrations (in ng/mL) of total IL-1 (3 are shown. ND = 
not detectable.
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Table 4. RIA for IL-1 a production in MNCs stimulated 
with LPS or TSST-1.____________________________
LPS (ng/mL) TSST-1 (ng/mL)
Donor no. control 10 1.0 0.1 10 1.0 0.1
6 ND 30.0 17.4 6.5 2.4 2.2 0.7
7 ND 20.0 8.4 4.3 8.4 2.0 ND
8 1.0 40.0 13.0 7.0 17.0 10.0 3.8
9 0.5 8.8 20.0 20.0 7.0 2.7 0.5
10 ND 40.0 30.0 20.0 6.0 3.4 0.8
11 ND 36.0 22.0 16.0 5.8 2.8 0.8
12 0.6 21.0 14.0 5.3 6.0 3.0 1.6
13 ND 9.2 7.6 4.4 4.6 1.0 0.6
O)
c
Li.ZH
O)
c
COJC
Q.
NOTE. Total IL-a (supernatant plus cell associated) was 
quantified. Samples were diluted K3, and concentrations were 
calculated from the sensitive portion of the standard curve. Fi- «
nal concentrations (in ng/mL) of total TNF are shown. ND = 7
not detectable. -
recombinant TNF at a dose of ng/kg also in­
duces profound hypotension (30% fall in mean ar­
terial pressure) in dogs [25] and rats [26]. A rabbit 
antibody to murine TNF protected BALB/c mice 
against the lethal effects of E. coli endotoxin [27]. 
Thus there is a growing concept that septic shock 
is mediated by TNF and that IL-1 also contributes 
to the septic-shock syndrome.
Here we demonstrate that purified TSST-1 causes 
release of TNF-like activity into the rabbit blood­
stream. Hence circulating TNF as well as IL-1 may 
provide a mechanism for toxic shock syndrome. Of 
considerable importance to the present study is the 
observation that in TSST-l-induced shock, the on­
set of hypotension coincided with the time for syn­
thesis and release of TNF-like substances and IL-1. 
Because TNF and IL-1 produce hypotension within 
15-20 min after iv injection, our findings suggest that 
the amount of TSST-1 we used in our model is not 
by itself exerting a direct effect in blood pressure, 
but rather that the induction of mediators, such as 
IL-1 and TNF, is first required. Although the half- 
life of iv-injected recombinant human TNF in the 
rabbit is 10 min (authors’ unpublished data) in the 
rabbit model we used, TSST-1 probably induces TNF 
and TNF-like activity for several hours. We previ­
ously demonstrated [3] that iv injection of filtrate 
from bacteria producing TSST-1 caused a sustained 
fever in rabbits. Plasma from TSST-l-injected rab­
bits that were bled during the peak of the fever pro­
duced, in recipient rabbits, a brief monophasic fe­
ver typical of endogenous pyrogen [3]. The combina­
tion of IL-1 and TNF has been shown to induce a 
shock-like state, as indicated by changes in several
Maximal Response Maximal Response 
to LPS to TSST-1
Figure 6. Comparison of maximal production of the 
cytokines TNF (top), IL-1 a (middle), and IL-1 P (bottom) 
in human MNCs stimulated with LPS or TSST-1. Data 
are derived from tables 2-4.
hemodynamic parameters and a pulmonary-capil- 
lary-leak syndrome [16].
We confirmed our in vivo findings by demonstrat­
ing that TSST-1 induces TNF production in vitro. 
We showed that TSST-1 induces a TNF-like activity 
from rabbit MNCs. However, because no immuno­
assay system for rabbit TNF is available, we cannot 
conclude that the TNF-like activity in rabbit MNC 
cultures or rabbit sera is identical to rabbit TNF. Our 
rabbit antiserum to human TNF does not neutral­
ize rabbit TNF. Supernatants from human MNCs 
incubated with TSST-1 were partially neutralized by 
1% antiserum to human TNF in cytotoxicity assays. 
Concentrations of these supernatants ranging from 
10% to 25% showed a similar percentage of un- 
neutralized cytotoxicity (20%-30%). This observa­
tion raises the possibility that TSST-1 induces both 
TNF and a substance that possesses TNF-like activ­
ity but that is antigenically distinct.
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Recently two groups reported the production of 
TNF by human blood MNCs [28, 29] by using the 
L929 cytotoxicity assay. Our results extend these 
studies by showing that TSST-1 induces TNF, IL-1 a, 
and IL-1 (3 from MNCs, as determined by specific 
RIAs. The biologic rationale for induction of both 
TNF and IL-1 by TSST-1 is unclear. However, sev­
eral studies have shown that the biologic effects of 
TNF and IL-1 are greatly enhanced when both 
cytokines are present together. IL-1 and TNF syner- 
gistically act on the inhibition of the proliferation 
of melanoma cells [30], the augmentation of pros­
taglandin E2 production from human lung fibroblast 
lines [31], insulin secretion from the islets of Lang- 
erhans of the rat pancreas [32], and the induction 
of a shock-like state in rabbits [16]. Using the com­
bination of both cytokines, which were given in doses 
that by themselves induced no significant hemo­
dynamic changes, a dramatic decrease in mean ar­
terial pressure was observed [16]. The hemodynamic 
changes caused by the combination of the low doses 
(1 Mg/kg each) of IL-1 plus TNF were nearly the same 
as those produced by a single bolus injection of 5 
Hg of TNF/kg alone, a dose that induces circulating 
IL-1 [9]. Thus the effects of these cytokines are syn­
ergistic but not additive.
We examined various tissues after TSST-l-induced 
shock, and the lung was the only organ significantly 
affected. Hemorrhage and hepatization were ob­
served. In various studies the combination of TNF 
and IL-1 also induced hemorrhage and hepatization 
and, in addition, massive accumulation of protein- 
aceous fluid and cells in the alveolar spaces [16]. 
These observations suggest that TSST-l-induced IL-1 
and TNF may act together in disrupting the pulmo­
nary vascular endothelium. After TSST-1 injection 
we also observed a fall in the peripheral white blood 
cell count, an occurrence that has been reported in 
humans receiving TNF [33] as well as in rabbits 
receiving TNF/IL-1 [16].
Studies on production of immunoreactive IL-1 a, 
IL-1 [3, and TNF in human MNCs induced by either 
LPS or TSST-1 may shed some light on toxic shock 
syndrome. Because the three major cytokines were 
quantified by RIA, doubts cannot be raised about 
interfering substances in bioassays for these cyto­
kines. Our results indicate that TSST-1 is a more po­
tent inducer of TNF than is LPS in MNCs from eight 
of 11 donors tested for this comparison. On the other 
hand, IL-1 (both a  and (3) was induced to a greater 
degree by LPS than by TSST-1 in these same MNCs.
These results suggest that the severity of the clinical 
response to TSST-1 may depend in part on the 
amount of TNF the individual produces when chal­
lenged with TSST-1. Further studies will be neces­
sary to correlate, if possible, the susceptibility to toxic 
shock syndrome with the amount of each cytokine 
(IL-1 and TNF) produced in response to TSST-1.
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